Strategy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst
The US FDA gives Sweden's privately held Modus Therapeutics rare pediatric disease designation for sickle cell disease.
Strategy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Strategy
AstraZeneca Bolstering India Play With $90m Investment Plan
AstraZeneca expects to invest $90m over five years to shore up its footprint in India – a market where the Anglo-Swedish major has introduced a string of new products but has also had a fair share of challenges.
Pfizer Seeks To Block Infringement Of Sutent Patent In India
Secarna MD On Standing Out In A Crowd
Secarna's managing director Jonas Renz talks about the company's antisense platform and partnering strategy.
Orchard To Use Divested GSK Rare Disease Gene Therapies To Grow Globally
Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.
Eisai Primes Push For Biogen MS Range In India
Eisai is straddling a mix of new opportunities for growth in India as it takes charge of sales of Biogen’s multiple sclerosis portfolio in the country and also eyes potential gains from its Japanese parent’s recent deal with Nichi-Iko.
Alexion's Pipeline Rebuild Plan Targets Wilson's Liver Drug, More M&A Likely
Swedish target's sole product WTX101 is in Phase III trials for treating Wilson Disease. Alexion says expect more deals.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.